Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2015 | 03-2014 | 03-2013 | 03-2012 | 03-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,934,547 | 6,660,480 | 3,504,310 | 2,729,030 | 10,514,570 |
| Marketable Securities | 557,603 | 1,849,810 | 3,122,910 | 3,057,390 | 18,160 |
| Receivables | 4,248,144 | 4,426,640 | 4,142,620 | -36,250 | 3,381,620 |
| Inventories | 2,387,421 | 2,543,290 | 2,777,320 | 1,289,050 | 1,652,130 |
| Other current assets | 704,946 | 445,140 | 4,059,320 | 9,204,020 | 3,544,990 |
| TOTAL | $13,832,660 | $15,925,360 | $17,606,480 | $16,243,240 | $19,111,470 |
| Non-Current Assets | |||||
| PPE Net | 4,788,074 | 5,422,530 | 6,184,320 | 6,206,510 | 5,145,450 |
| Investments And Advances | 2,565,891 | 2,348,900 | 2,150,650 | 2,371,050 | 1,988,180 |
| Intangibles | 16,027,757 | 19,502,680 | 0 | 0 | 0 |
| Other Non-Current Assets | 1,880,948 | 2,491,960 | 21,921,270 | 20,607,450 | 7,325,990 |
| TOTAL | $25,262,670 | $29,766,070 | $30,256,240 | $29,185,010 | $14,459,620 |
| Total Assets | $39,095,350 | $45,691,440 | $47,862,740 | $45,428,280 | $33,571,100 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 909,682 | 1,554,040 | 0 | 3,065,910 | 26,950 |
| Accounts payable and accrued liabilities | 1,554,116 | 1,849,000 | 2,634,710 | 0 | 967,710 |
| Accrued Expenses | N/A | N/A | 1,767,670 | 2,161,070 | 2,011,940 |
| Other current liabilities | 6,415,563 | 4,101,190 | 1,628,330 | 2,719,190 | 1,725,060 |
| TOTAL | $9,253,099 | $8,027,540 | $7,424,940 | $9,546,980 | $5,260,190 |
| Non-Current Liabilities | |||||
| Long Term Debt | 5,727,686 | 7,045,800 | 6,535,920 | 3,827,690 | 197,430 |
| Other Non-Current Liabilities | 2,592,617 | 2,376,800 | 2,909,510 | 1,699,430 | 1,017,680 |
| TOTAL | $9,766,047 | $12,257,550 | $13,535,120 | $9,568,580 | $2,568,060 |
| Total Liabilities | $19,019,150 | $20,285,090 | $20,960,100 | $19,115,580 | $7,828,260 |
| Shareholders' Equity | |||||
| Common Shares | 582,800 | 635,620 | 768,840 | 806,970 | 765,550 |
| Retained earnings | 14,572,070 | 19,013,070 | 27,141,660 | 28,626,750 | 27,374,300 |
| Other shareholders' equity | 4,545,197 | 5,365,000 | -1,477,370 | -3,741,430 | -2,983,050 |
| TOTAL | $20,076,200 | $25,406,350 | $26,902,640 | $26,312,690 | $25,742,840 |
| Total Liabilities And Equity | $39,095,350 | $45,691,440 | $47,862,740 | $45,428,270 | $33,571,100 |